Astellas and Teva reach US settlement over generic Vesicare
This article was originally published in Scrip
Astellas and Teva Pharmaceutical Industries have agreed to settle litigation concerning a US patent for Astellas's overactive bladder drug, Vesicare (solifenacin succinate).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.